We are live on ! Find out more
RTW Investments

RTW Investments Portfolio holdings

AUM $11.7B Turnover 22.68%
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+27.09%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$11.7B
AUM Growth
+$1.66B
Cap. Flow
-$50.3M
Cap. Flow %
-0.43%
Top 10 Hldgs %
47.72%
Holding
97
New
9
Increased
26
Reduced
8
Closed
13
Avg Time Held
2.1 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
KLRA icon
Kailera Therapeutics
KLRA
+$237M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$103M
3
CGON icon
CG Oncology
CGON
+$100M
4
ORKA icon
Oruka Therapeutics
ORKA
+$72M
5
GPCR icon
Structure Therapeutics
GPCR
+$71.1M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$234M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$148M
3
COGT icon
Cogent Biosciences
COGT
+$110M
4
ISRG icon
Intuitive Surgical
ISRG
+$101M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$81.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Financials 0.07%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$10.4B
$1.07B 9.14%
1,993,687
– –
2023 Q2
12 quarters
ARGX icon
2
argenx
ARGX
$51.5B
$658M 5.62%
709,446
– –
2017 Q2
36 quarters
PTCT icon
3
PTC Therapeutics
PTCT
$4.94B
$632M 5.39%
7,746,415
– –
2016 Q4
38 quarters
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.33B
$620M 5.3%
5,061,175
+2,122
+0% +$222K
2019 Q3
27 quarters
CGON icon
5
CG Oncology
CGON
$5.31B
$605M 5.16%
8,514,590
+1,529,782
+22% +$100M
2024 Q1
9 quarters
INSM icon
6
Insmed
INSM
$21B
$516M 4.41%
4,842,880
– –
2023 Q2
12 quarters
TNGX icon
7
Tango Therapeutics
TNGX
$3.72B
$435M 3.71%
13,900,620
+600,000
+5% +$14.8M
2025 Q4
2 quarters
SYRE icon
8
Spyre Therapeutics
SYRE
$7.47B
$377M 3.22%
4,251,996
+80,000
+2% +$5.84M
2023 Q4
10 quarters
CELC icon
9
Celcuity
CELC
$2.77B
$346M 2.95%
3,304,903
+265,282
+9% +$30.6M
2025 Q4
2 quarters
ERAS icon
10
Erasca
ERAS
$4.68B
$329M 2.81%
17,946,754
+1,789,579
+11% +$25.6M
2025 Q4
2 quarters
RDNT icon
11
RadNet
RDNT
$5.41B
$299M 2.55%
4,846,958
+561,958
+13% +$31.6M
2023 Q4
10 quarters
ORKA icon
12
Oruka Therapeutics
ORKA
$4.76B
$299M 2.55%
3,139,030
+1,080,882
+53% +$72M
2024 Q2
8 quarters
NTRA icon
13
Natera
NTRA
$56.7B
$271M 2.32%
1,000,000
-250,000
-20% -$53.3M
2019 Q3
27 quarters
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$1.43B
$260M 2.22%
7,796,895
+4,148,100
+114% +$103M
2021 Q4
18 quarters
IRTC icon
15
iRhythm Holdings
IRTC
$3.58B
$260M 2.22%
2,182,631
+514,131
+31% +$59.8M
2025 Q4
2 quarters
CYTK icon
16
Cytokinetics
CYTK
$8.61B
$244M 2.08%
2,862,003
+140,845
+5% +$10.1M
2020 Q3
23 quarters
KLRA icon
17
Kailera Therapeutics
KLRA
$1.46B
$237M 2.03%
+10,776,820
New +$237M
2026 Q2
0 quarters
ESTA icon
18
Establishment Labs
ESTA
$1.76B
$228M 1.95%
2,655,695
– –
2018 Q3
31 quarters
GH icon
19
Guardant Health
GH
$21.3B
$222M 1.9%
1,481,033
– –
2025 Q2
4 quarters
NBIX icon
20
Neurocrine Biosciences
NBIX
$13.8B
$214M 1.82%
1,267,925
+205,853
+19% +$30.5M
2025 Q2
4 quarters
TARS icon
21
Tarsus Pharmaceuticals
TARS
$3.19B
$211M 1.8%
3,357,059
+11,034
+0.3% +$705K
2020 Q4
22 quarters
STOK icon
22
Stoke Therapeutics
STOK
$1.56B
$184M 1.57%
5,623,525
– –
2019 Q2
28 quarters
QURE icon
23
uniQure
QURE
$1.51B
$182M 1.55%
3,941,572
+1,355,216
+52% +$35.5M
2024 Q3
7 quarters
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$3.29B
$181M 1.54%
7,144,524
– –
2022 Q2
16 quarters
RGEN icon
25
Repligen
RGEN
$11.1B
$169M 1.45%
1,240,637
+34,637
+3% +$4.26M
2025 Q4
2 quarters
1
2 3 4

Similar funds

Centersquare Investment Management
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
Mediolanum International Funds
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
Quadrature Capital
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Unisphere Establishment
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
Focus Partners Advisor Solutions
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CMT Capital Markets Trading
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Haverford Trust Company
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return

RTW Investments's Q2 2026 Portfolio in Review

As of Q2 2026, RTW Investments held 97 positions worth $11.7B, up 17% from $10B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

RTW Investments's Q2 2026 filing shows 9 new, 26 increased, 8 reduced and 13 closed positions. Its largest new stake was Kailera Therapeutics: 10,776,820 shares worth $237M. The largest sale was Apogee Therapeutics, an estimated $234M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RTW Investments's largest Q2 2026 buy was Kailera Therapeutics: 10,776,820 shares worth $237M.
  • RTW Investments added most to Ultragenyx Pharmaceutical in Q2 2026, an estimated $103M increase.
  • RTW Investments's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $110M.
  • RTW Investments fully exited Apogee Therapeutics in Q2 2026, selling an estimated $234M.
  • RTW Investments's ten largest holdings make up 48% of its $11.7B portfolio in Q2 2026.
  • RTW Investments opened 9 new positions and closed 13 in Q2 2026.
  • RTW Investments's portfolio value rose 17% quarter-over-quarter to $11.7B.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.